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Abstract 
Background: Helminthiases are very prevalent worldwide, yet their treatment and control rely on a handful of drugs. 
Emodepside, a marketed broad-spectrum veterinary anthelminthic with a unique mechanism of action, undergoing 
development for onchocerciasis is an interesting anthelmintic drug candidate. We tested the in vitro and in vivo activ-
ity of emodepside on nematode species that serve as models for human soil-transmitted helminth infection as well as 
on schistosomes.
Methods: In vitro viability assays were performed over a time course of 72 hours for Trichuris muris, Necator ameri-
canus, Ancylostoma ceylanicum, Heligmosomoides polygyrus, Strongyloides ratti, Schistosoma mansoni and Schistosoma 
haematobium. The drug effect was determined by the survival rate for the larvae and by phenotypical scores for the 
adult worms. Additionally, mice infected with T. muris and hamsters harboring hookworm infection (N. americanus or 
A. ceylanicum) were administered orally with emodepside at doses ranging from 1.25 to 75 mg/kg. Expelled worms 
in the feces were counted until 3 days post-drug intake and worms residing in the intestines were collected and 
counted after dissection.
Results: After 24 hours, emodepside was very active in vitro against both larval and adult stages of the nematodes 
T. muris, A. ceylanicum, N. americanus, H. polygyrus and S. ratti  (IC50 < 4 µM). The good in vitro activity was confirmed 
in vivo. Hamsters infected with the hookworms were cured when administered orally with 2.5 mg/kg of the drug. 
Emodepside was also highly active in vivo against T. muris  (ED50 = 1.2 mg/kg). Emodepside was moderately active on 
schistosomula in vitro  (IC50 < 8 µM) 24 h post-drug incubation and its activity on adult S. mansoni and S. haematobium 
was low  (IC50: 30–50 µM).
Conclusions: Emodepside is highly active against a broad range of nematode species both in vitro and in vivo. The 
development of emodepside for treating soil-transmitted helminth infections should be pursued.
Keywords: Emodepside, Drug repurposing, Soil-transmitted helminthiases (STH), Hookworms, Trichuris spp., 
Nematodes, Trematodes, Schistosoma spp.
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Background
Helminths affect a fifth of the world population and their 
associated morbidities include general fatigue, food mal-
absorption or iron deficiency anemia [1–4]. They are an 
important public health issue in low and middle income 
countries, where they enhance the vicious cycle of pov-
erty notably by reducing school attendance and pro-
ductivity [5, 6]. The most prevalent helminthiases are 
schistosomiasis (primarily caused by Schistosoma hae-
matobium, S. japonicum and S. mansoni) that affects 
more than 250 million people and soil-transmitted hel-
minthiases (STH) that account for more than 1.5 billion 
infected cases worldwide [2, 4, 6, 7]. Infections with the 
hookworms Ancylostoma duodenale and Necator ameri-
canus, the whipworm Trichuris trichiura, the roundworm 
Ascaris lumbricoides and the threadworm Strongyloides 
stercoralis are grouped as soil-transmitted helminths, 
based on their mode of transmission [8, 9].
Preventive chemotherapy is the strategy of choice, 
recommended by the World Health Organization 
(WHO) to control these helminth infections. Schisto-
somiasis control relies on praziquantel while albenda-
zole, mebendazole, levamisole and pyrantel pamoate 
are used against STH [7, 10, 11]. A recent meta-analysis 
showed that all four drugs used against STH have a lim-
ited and even decreasing efficacy against the parasites 
[12]. Also, the recent epidemiological survey from Crel-
len et  al. [13] reported that the efficacy of praziquan-
tel against S. mansoni was reduced, likely because of 
frequent mass drug administration campaigns (MDA). 
Together with the rising risk of drug resistance due to 
an intense use of the same drugs and the lack of lead 
molecules in the development pipeline, the discovery of 
new anthelmintic treatments is urgent [12, 14, 15].
As the expected return on investment for helminthi-
ases is negligible, drug repurposing represents a sus-
tainable approach and an effective strategy to expand 
the pool of active molecules, in particular when using 
veterinary anthelmintics as starting point [16]. Emod-
epside, is a broad-spectrum veterinary anthelmintic 
licensed under the name of Profender® and Procox® 
and is used in combination with praziquantel and tol-
trazuril, respectively [17]. Its activity has been dem-
onstrated against a wide range of nematodes in the 
veterinary field [18–25]. Repurposing emodepside for 
human use started more than ten years ago with pre-
clinical studies against filarial nematodes which may 
be considered surrogates of human filarial infections 
[26]. These promising results triggered in 2016 a phase 
I study with emodepside in healthy volunteers, which 
was then completed by single and multiple ascending 
dose studies [17, 27].
Aiming at possibly expanding its range of applica-
tion in human medicine and in order to broaden previ-
ous work on laboratory models, we thoroughly tested 
emodepside against seven species of helminths in vitro 
and in vivo [28–30]. The drug was tested first in vitro on 
both larval and adult stages of T. muris, A. ceylanicum, 
N. americanus, S. ratti and H. polygyrus, as well as on S. 
mansoni and S. haematobium. The activity of emodep-
side was next tested in vivo in animal models infected 
with T. muris, A. ceylanicum and N. americanus. The 
experimental flow for the study on nematodes is pre-
sented in Fig. 1.
Fig. 1 Workflow for the nematode assays
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Methods
Drugs
Emodepside was purified by preparative high-perfor-
mance liquid chromatography (HPLC) from the com-
mercially available topical solution for cats Profender® 
(Bayer, Leverkusen, Germany). Profender® was diluted 
1:1 (v/v) with acetonitrile (ACN), filtered (0.22 µm) and 
injected (10 mL) into a preparative HPLC (Varian ProS-
tar system). The purification was performed on a Repro-
Sil® 100 C18, 7 µm, 250 × 40 mm column (Dr. Maisch 
GmbH, Ammerbuch-Entringen, Germany) with double 
distilled water, 0.1% Trifluoroacetic acid (TFA) as solvent 
A and HPLC grade ACN (Buchs, Sigma-Aldrich) as sol-
vent B at 20 ml/min flowrate. The following linear gradi-
ent was used: 0 min 20% B; 0.5 min 20% B; 34 min 100% 
B; 40 min 100% B. Fractions containing emodepside were 
then combined and lyophilized.
Emodepside’s 1H- and 13C-NMR spectra were recorded 
on Bruker 400 and 500 spectrometers and referenced to 
residual solvent peaks. LC-MS spectra of the purified 
compound were measured on an Acquity™ (Waters sys-
tem) coupled to an Esquire HCT from Bruker (Bremen, 
Germany) using an Acquity UPLC BEH C18 column 
(2.1 × 50 mm, 1.7  μm) at 0.6  ml/min flow with a linear 
gradient of A (double distilled water 0.1% v/v formic 
acid) and B (ACN 0.1% v/v formic acid); t = 0 min, 5% B; 
t = 0.25 min, 5% B; t = 1.5 min, 100% B; t = 2.5 min, 100% 
B. NMR and MS spectra corresponded to that previously 
reported for emodepside (Segment solid-phase total 
synthesis of the anthelmintic cyclooctadepsipeptides 
PF1022A and emodepside) [31].
Levamisole was purchased in powder from Sigma-
Aldrich (Buchs, Switzerland). Stock solutions of emod-
epside and levamisole (10  mM) were dissolved in pure 
dimethyl sulfoxide (DMSO, Sigma-Aldrich, Buchs, Swit-
zerland) and stored until use at − 20 °C.
Culture media
RPMI 1640 (Gibco, Waltham MA, USA) medium sup-
plemented with 5% amphotericin B (250  µg/ml, Sigma-
Aldrich, Buchs, Switzerland) and 1% penicillin 10,000 U/
ml, and streptomycin 10 mg/ml solution (Sigma-Aldrich, 
Buchs, Switzerland) was used for the assays with T. muris 
adults and stage 1 larvae (L1), H. polygyrus adults and 
supplemented additionally with 10% inactivated fetal calf 
serum (iFCS; Bioconcept AG, Allschwil, Switzerland) for 
T. muris L1 hatching medium. RPMI 1640 supplemented 
with 5% amphotericin B (250  µg/ml), 1% penicillin 
(10,000 U/ml) and streptomycin (10 mg/ml) solution and 
1% of the antibiotics mixture developed by Mäser et  al. 
[32] was used for the H. polygyrus third stage larval (L3) 
assays. Adult S. mansoni, S. haematobium and S. ratti 
were incubated in RPMI 1640 medium supplemented 
with 5% iFCS and 1% penicillin (10,000 U/ml) and 
streptomycin (10 mg/ml) solution. Phosphate-buffered 
saline (PBS, Sigma-Aldrich, Buchs, Switzerland) supple-
mented with 1% penicillin (10,000 U/ml) and streptomy-
cin (10 mg/ml) solution was used to incubate S. ratti L3 
and to wash the adult worms. For the S. mansoni newly 
transformed schistosomula (NTS) assays, M199 medium 
(Gibco, Waltham MA, USA) supplemented with 5% iFCS 
and a mixture of antibiotics was used for the incubation 
[33]. Ancylostoma ceylanicum and N. americanus L3 
stages were incubated in Hanksʼ balanced salt solution 
(HBSS; Gibco, Waltham MA, USA) supplemented with 
10% amphotericin B and 1% penicillin (10,000 U/ml) and 
streptomycin (10 mg/ml) solution. The adult hookworms 
were kept in HBSS supplemented with 10% iFCS, 5% 
amphotericin B (250 µg/ml) and 1% penicillin (10,000 U/
ml) and streptomycin (10 mg/ml) solution.
Laboratory animals
Before the infection, all animals were left one week for 
acclimation in our facility. Three-week-old male Syr-
ian golden hamsters (Charles River, Sulzfeld, Germany) 
were orally infected with 150 L3 of A. ceylanicum or sub-
cutaneously with 150 N. americanus L3. Four-week-old 
female NMRI mice (Charles Rivers, Sulzfeld, Germany) 
were used for S. mansoni infection and injected subcu-
taneously with 100 cercariae. The same mice strain was 
used for growing H. polygyrus which were administered 
orally with 88 L3. Six-week-old female C57BL/6NRj mice 
(Janvier labs, Le Genest-Saint-Isle, France) were orally 
infected with 200 embryonated T. muris eggs. Three-
week-old male Wistar rats (Janvier labs, Le Genest-Saint-
Isle, France), were infected subcutaneously with 1300 S. 
ratti L3. Three-week-old male LVG Syrian Golden ham-
sters (Charles River, USA) were infected with S. haema-
tobium cercariae at the Biomedical Research Institute 
(Atlanta, USA) before being sent to the Swiss Tropical 
and Public Health Institute.
All animals were kept in polycarbonate cages under 
environmentally-controlled conditions (temperature: 
25 °C, humidity: 70%, 12:12 h light/dark photocycle) and 
had free access to tap water and rodent food. To guar-
antee a sustainable infection, dexamethasone (Sigma-
Aldrich, Buchs, Switzerland) was supplied in the drinking 
water until 2 days before treatment for the NMRI mice 
infected with H. polygyrus (0.25  mg/l dexamethasone), 
the C57BL/6NRj mice infected with T. muris (1 mg/l dex-
amethasone) and the hamsters infected with the hook-
worms (0.5  mg/l dexamethasone).  Animals were killed 
using the  CO2 method to collect the adult worms for the 
in vitro studies as described below.
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Drug assays
To determine the half maximal inhibitory concentration 
 (IC50) of the drug, each compound and concentration 
was tested in triplicates in the larval assays and in dupli-
cates in adult worm assays. Parasites incubated in wells 
containing culture medium and DMSO corresponding to 
the highest drug concentration, served as negative con-
trols and were included in every in vitro assay.
Heligmosomoides polygyrus, S. ratti and A. ceylani-
cum L3 larvae were then kept in the dark and at room 
temperature for 72  h. Strongyloides ratti L3 plates were 
sealed with Parafilm (Faust AG, Schaffhausen, Switzer-
land) before incubation. T. muris L1, N. americanus L3, 
S. mansoni NTS and the adult assays of all seven species 
were kept in the incubator for 72 h at 37 °C and 5%  CO2.
In vitro tests on N. americanus and A. ceylanicum L3
Necator americanus and A. ceylanicum L3 were obtained 
from infected hamsters by the cultivation of eggs, gained 
by repeated filtration and centrifugation of the infected 
feces. The eggs were washed with tap water and culti-
vated on agar plates protected from light for 8 to 10 days 
at room temperature. The L3 were then kept in tap water 
supplemented with 5% amphotericin B (250  µg/ml), 
1% penicillin (10,000  U/ml) and streptomycin (10  mg/
ml) solution and used within 3 weeks. In each well of a 
96-well plate (Sarstedt, Nümbrecht, Germany), 30 L3 
were exposed to 4 serial dilutions (1:4) ranging from 
0.016 µM up to 1 µM emodepside concentrations in a 
final volume of 200 µl.
In vitro tests on adult N. americanus and A. ceylanicum
Five weeks to six weeks post-infection (p.i.), the worms 
were collected directly from the hamster’s intestines. In 
a 24-well plate (Sarstedt, Nümbrecht, Germany), 3 to 
4 adult worms per well were incubated in 2.5  ml drug 
solution with 4 different concentrations ranging from 
0.005 µM to 0.5 µM for A. ceylanicum and with concen-
trations of 0.01 µM, 0.1 µM and 1 µM for N. americanus.
In vitro tests on T. muris L1
Six weeks after the infection of the mice, T. muris eggs 
were gained by filtration of their feces and storage in tap 
water for three months in the dark. To obtain the first 
stage larvae, egg hatching was triggered by incubation 
with Escherichia coli (BL21 strain) in hatching medium 
for 3 to 4  h at 37  °C in a wet chamber. For the assay, 
the L1 suspended in a total volume of 100 µl medium 
were placed in each well of a 96-well plate containing 
14 emodepside concentrations ranging from 0.098 µM 
to 100  µM. Wells that contained levamisole (25  µM or 
100 µM) served as positive control. The assays were kept 
in the incubator for 24 hours.
In vitro tests on adult T. muris
Trichuris muris adult worms were collected manually 
from the intestines of infected mice, 41  days p.i. The 
drug assays were performed in 24-well plates. In each 
well, 2 to 3 adult worms were incubated with the drug 
(1:4 serial dilutions ranging from 0.039  µM to 10  µM) 
in a final volume of 2.5 ml.
In vitro tests on H. polygyrus L3
The eggs were collected 2  weeks p.i. from mice feces 
and placed on agar at room temperature for 8 to 10 days 
in the dark. Forty L3 were exposed to emodepside at 3 
different concentrations (0.625 µM, 2.5 µM and 10 µM) 
in a final volume of 100 µl.
In vitro assay on adult H. polygyrus
Heligmosomoides polygyrus adults were collected 
2  weeks p.i. when dissecting mice intestines. In each 
well of 24-well plates 3 to 4 adult worms were exposed 
to emodepside (1:2 serial dilutions ranging from 
0.125 µM to 1 µM) in 2.5 ml culture medium.
In vitro studies on S. mansoni NTS
Schistosoma mansoni (Liberian strain) cercariae were 
harvested from infected Biomphalaria glabrata snails 
and were then transformed into NTS [33, 34]. The drug 
assays and phenotypic screening were performed as 
described previously [33].
In vitro studies on adult S. mansoni and S. haematobium
Seven weeks p.i. the worms were extracted from the 
rodent mesenteric veins. Three single flukes or 2 pairs 
were placed in a final volume of 2.4 ml in each well of 
a 24-well plate exposed to 1:3 serial dilutions ranging 
from 3.7 µM up to 33.33 µM emodepside.
In vitro studies on S. ratti L3
The L3 were obtained following the procedure 
described by Garcia (1998) [35]. Thirty L3 were 
exposed to emodepside (1:4 serial dilutions ranging 
from 0.039 µM to 10 µM) in a final volume of 100 µl.
In vitro studies on adult S. ratti
The infected rats were dissected 3 weeks p.i. The intes-
tines of the rats were excised, opened and immerged in 
PBS supplemented with penicillin/streptomycin. They 
were incubated for 4 h at 37 °C and 5%  CO2 in order to 
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detach the nematodes from the intestinal wall. A maxi-
mum of 15 worms were then transferred into the wells 
of 24-well plates and placed in 2  ml culture medium 
containing emodepside at 6 different concentrations 
ranging from 50 µM to 0.25 µM.
Evaluation of the assays
The drug effect was evaluated 24, 48 and 72 h post-expo-
sure. For evaluating the L3 assays, the larvae were stimu-
lated if necessary by the addition of 50 µl (T. muris L1) to 
100 µl  (others spp.) hot water (≈ 80 °C) and the percent-
age of survival was determined by the ratio of moving 
larvae to the total number of larvae present in the well. 
The N. americanus L3 assay was an exception as the wells 
were stimulated by vigorous up and down pipetting. The 
adult worms of each parasite species were scored micro-
scopically based on their phenotype, using a viability 
scale ranging from 3 to 0 (3: good motility and no mor-
phological changes; 2: low motility and light changes in 
morphology; 1: very low motility and morphologically 
impaired; and 0: death). In case the adult worms did not 
move enough for a clear scoring, they were stimulated 
with hot water at the last evaluation time-point.
Trichuris muris in vivo studies
C57BL/6NRj mice were orally infected with 200 embryo-
nated T. muris eggs. At 42 days p.i., the feces were col-
lected and soaked for 1 hour in 0.9% sodium chloride, 
before the filtered suspension was examined under the 
microscope to determine the success of the infection. 
According to their infection intensities, the mice were 
equally assigned to the different groups. The compound 
was dissolved in 70:30 Tween 80-ethanol in ultrapure 
water (10% v/v) and was administered by gavage first 
at a dose of 75 mg/kg based on results from a previous 
study [28] followed by lower dosages from 1.25 to 10 mg/
kg. Untreated mice served as controls. Until 3 days after 
drug administration the feces of the mice were examined 
for expelled worms. Six to seven days post-treatment, the 
animals were killed, their intestines were dissected, and 
the adult worms were collected and counted.
Ancylostoma ceylanicum and N. americanus in vivo studies
Hamsters were orally infected with 150 A. ceylanicum L3 
or subcutaneously with 150 N. americanus L3. A fecal 
sample was collected from each hamster, just before 
treatment. The fecal samples were processed using an 
in-house sedimentation method to determine the infec-
tion intensity of each animal [36]. The different dosage 
and control groups were composed of hamsters evenly 
distributed depending on their infection status. A. cey-
lanicum infected hamsters were then treated on day 28 
p.i. with a single oral dose of 2.5 mg/kg emodepside and 
N. americanus infected hamsters with a single oral dose 
of 1.25–10  mg/kg emodepside. Expelled worms were 
counted from each hamster from the collected feces until 
72 h after treatment. One week post-treatment, the ham-
sters were euthanized and the worms remaining in their 
intestines were collected and counted.
Data analysis
For the in vitro drug sensitivity assays, all viability scores 
and larval survival counts were averaged across replicates 
and normalized to the control wells. The effect of emod-
epside was determined by normalizing the mean parasite 
survival rate to the control wells. Based on these values, 
the  IC50 values were calculated using CompuSyn software 
(ComboSyn Inc., version 1.0), as well as the r-values (the 
linear correlation coefficient) that reflects the goodness 
of the fit. For each assay, a minimal r value and viability of 
the controls was required. The detailed selection criteria 
are presented in Table 1.
To assess the effect of the drug in vivo, the mean num-
bers of living worms recovered in treated animals were 
compared to the controls. The worm burden reduction 
(WBR) was calculated as described previously [16]. The 
worm expulsion rate (WER) was determined by the num-
ber of dead worms excreted in the feces during 72 h after 
treatment, over the total number of worms (alive and 
dead) recovered during the necropsy. The Kruskal-Wallis 
test (Statsdirect version 3.1.20) were used to determine 
statistical significance of WBR at a level of 0.05. The 
median effective dose  (ED50) values were calculated using 
CompuSyn software (ComboSyn Inc., version 1.0).
Results
In vitro studies
Table 1 and Additional files 1 and 2 summarize the mean 
 IC50 values for each helminth species over 3 days post-
drug exposure, except for T. muris L1 that were assessed 
after a 24 h incubation period. Emodepside showed  IC50 
values below 1 µM, within 24  h for all nematode spe-
cies with the exception of T. muris L1 that had an  IC50 
of 3.7  µM. The highest drug activity was observed for 
adult hookworms. After one day of incubation, emod-
epside was highly active against adult A. ceylanicum 
and N. americanus with  IC50 values below 0.005  µM, 
which were reduced by half over the incubation period 
 (IC50 < 0.0025  µM). Decreasing  IC50 values were also 
recorded over the 72 h incubation period for the adult 
worms of every species tested. Against T. muris adults 
emodepside showed an  IC50 value below 0.3  µM after 
24  h of drug exposure. This value decreased below 
0.05  µM after another day of incubation.  IC50 values in 
the range of 0.2 µM to 0.8 µM were observed for adult H. 
polygyrus and S. ratti.
Page 6 of 10Karpstein et al. Parasites Vectors          (2019) 12:226 
IC50 values for all nematode L3 ranged from 0.9 µM to 
0.08 µM. The  IC50 values of S. ratti and N. americanus L3 
decreased, while they decreased and increased over the 
3 days incubation period for H. polygyrus and A. ceylani-
cum larvae, respectively. For the schistosomes S. man-
soni and S. haematobium,  IC50 values above 30 µM were 
calculated for adult worms while decreasing  IC50 from 
7.8 µM after 24 h to 2.5 µM after 72 h were observed for 
S. mansoni NTS.
For all the nematode species, the  IC50 values were 
higher for the larval stages than for the adult worms. 
Strongyloides ratti was the only species where the dif-
ference between the two life-stages was less than 2-fold. 
The  IC50 on adult worms was of about twice as high 
than for the larval stage for H. polygyrus, 13 times for T. 
muris and between 30 to 250 times for the hookworms N. 
americanus and A. ceylanicum. The exact opposite was 
observed for S. mansoni. At the 24 h and 48 h evaluation 
time-points, the  IC50 values on NTS were 5 to 7 times 
lower than the ones measured on adult S. mansoni. When 
assessed after 3 days, a 13-fold difference was observed 
between S. mansoni NTS and the adult worms.
Emodepside was lethal (100% effect) in vitro on A. 
ceylanicum adults, S. ratti L3 and both life stages of N. 
americanus. Drug effects above 90% were observed at a 
concentration of 25 µM emodepside for T. muris L1 and 
at a concentration of 2.5 µM for adult worms. This was 
also the case for A. ceylanicum when incubated at 1 µM 
(L3) or 0.1  µM (adults) and N. americanus at 0.25  µM 
(L3) or 0.1  µM (adults). Effects of more than 75% were 
reached at 2.5 µM for H. polygyrus L3 and at 0.5 µM for 
adult worms. Emodepside had an effect above 75% at a 
concentration of 2.5   µM on S. ratti (L3) and showed a 
similar effect at a 10 times lower concentration when 
tested on adult worms.
In vivo studies
The worm expulsion rates and worm burden reductions 
obtained with single-dose, oral emodepside against T. 
muris are summarized in Table 2. A high dose of 75 mg/
kg emodepside resulted in complete elimination of all 
worms. At doses of 10 mg/kg and 2.5 mg/kg worm bur-
den reductions of 85.9% and 69.6% and worm expulsion 
rates of 62.0% and 60.9%, respectively were observed. The 
lowest dose tested (1.25 mg/kg) showed low activity, with 
a worm burden reduction of 73.9% and worm expulsion 
rate of 5.3%. The worm burden reductions obtained with 
emodepside (all doses versus controls) were statistically 
significant (t = 7.18, P = 0.0073). Based on worm burden 
reductions we calculated an  ED50 value of 1.2 mg/kg.
Single doses of 10  mg/kg and 5  mg/kg cured all N. 
americanus-infected hamsters. A worm burden reduc-
tion of 93.8% and a worm expulsion rate of 87.5% were 
observed at a dose of 2.5  mg/kg. Moderate activity 
(worm burden reduction of 43.8% and worm expulsion 
rate of 40.0%) was observed in N. americanus-infected 
hamsters with the lowest dose tested of 1.25 mg/kg 
(all doses, t = 3.52, P = 0.06). An  ED50 value of 0.5  mg/
Table 1 Mean  IC50 values in vitro of emodepside tested on larval and adult stages of different helminths
a Each assay included 2 to 3 wells per concentration/condition
Notes: The inclusion criteria used in our analysis were different for each stage and parasite. Minimal survival rates (larvae) or viability scores (adults and NTS) and 
 IC50 r-values considered acceptable were as follows: T. muris L1 (survival rate: 60%; R = 0.7), adults (score: 2.5; R = 0.8); H. polygyrus L3 (70%; 0.9), adults (1.9; 0.8); A. 
ceylanicum L3 (55%; 0.7), adults (2; 0.7); N. americanus L3 (60%; 0.75), adults (2; 0.8); S. ratti L3 (60%; 0.75), adults (2; 0.7); S. mansoni NTS (2; 0.75), adults (1.5; 0.85); S. 
haematobium adults (2; 0.7)
Abbreviation: SD, standard deviation
Species Replicates No. of parasites 
per  wella
24 hours 48 hours 72 hours
Mean  IC50 ± SD (µM) Mean  IC50 ± SD (µM) Mean  IC50 ± SD (µM)
T. muris (L1) 9 20–40 3.73 ± 6.54 – –
T. muris (adults) 2 2–3 0.28 ± 0.15 0.043 ± 0.0089 0.022 ± 0.013
H. polygyrus (L3) 2 30 0.78 ± 0.086 0.9 ± 0.034 0.48 ± 0.05
H. polygyrus (adults) 3 3–4 0.57 ± 0.42 0.21 ± 0.13 0.25 ± 0.16
A. ceylanicum (L3) 2 30 0.14 ± 0.041 0.086 ± 0.08 0.25 ± 0.051
A. ceylanicum (adults) 3 2–3 0.0044 ± 0.0021 0.0015 ± 0.00078 0.0024 ± 0.002
N. americanus (L3) 2 30 0.77 ± 0.52 0.15 ± 0.069 0.083 ± 0.033
N. americanus (adults) 2 2–3 0.0031 ± 0.0011 0.0029 ± 0.0018 0.0021 ± 0.0012
S. ratti (L3) 4 30 0.73 ± 0.5 0.27 ± 0.21 0.25 ± 0.14
S. ratti (adults) 3 5–15 0.75 ± 0.57 0.21 ± 0.29 0.36 ± 0.32
S. mansoni (NTS) 2 100 7.79 ± 1.57 6.92 ± 0.21 2.48 ± 0.78
S. mansoni (adults) 2 2–3 50.4 ± 3.32 37.27 ± 10.47 34.1 ± 9.18
S. haematobium (adults) 2 2–3 40.51 ± 24.96 40.25 ± 6.49 36.73 ± 6.49
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kg was determined for emodepside in N. americanus-
infected hamsters. To confirm that emodepside also acts 
on Ancylostoma spp. the minimum effective dose on N. 
americanus of 2.5  mg/kg was tested in the A. ceylani-
cum hamster model, which resulted in cure of all animals 
(t = 6.05; P = 0.014).
Discussion
Given a promising activity against a wide range of resist-
ant worm infections and its unique mode of action, it is 
worthwhile to evaluate the activity of emodepside against 
other helminth infections including STH and schistoso-
miasis. For the first time we thoroughly tested emodep-
side against a wide range of laboratory models for these 
diseases.
Both the larval and the adult nematode and schisto-
some stages were screened phenotypically in presence 
of emodepside over a time course of 72 hours followed 
by in vivo studies. As emodepside belongs to the group 
of cyclooctadepsipeptides that are known to be very 
active against different animal gastrointestinal nematodes 
and filarial parasites, good antinematicidal activity was 
expected [20, 30, 37–40]. The drug showed a high efficacy 
in vitro against all the nematode species and was highly 
effective against the two hookworms (A. ceylanicum 
and N. americanus) and the whipworm (T. muris). On 
the contrary, the effect of emodepside on schistosomes, 
remained only moderate.
We further investigated the efficacy of emodepside in 
vivo on rodents infected with T. muris, A. ceylanicum and 
N. americanus. Overall, the promising in vitro activity of 
emodepside was confirmed in vivo, where the drug dem-
onstrated high worm burden reduction rates, even when 
administered orally as a low, single dose regimen.
These results were consistent with previous findings. 
The  ED50 value obtained in vivo for T. muris  (ED50 of 
1.2 mg/kg) was very similar to the one reported by Kulke 
et  al. [28]. Our study also confirms the good activity of 
emodepside in vitro against larval and especially adult 
stages of the nematodes S. ratti and H. polygyrus that was 
so far only described in vivo [29].
Emodepside performed much better in vitro and in 
vivo than albendazole, levamisole and pyrantel pamoate, 
the standard drugs used against STH infections tested 
in a previous study [36], where none of the standard 
drugs showed in vitro activity against adult A. ceylani-
cum (Table  3). Moreover, only a moderate in vitro effi-
cacy against T. muris and N. americanus was reached by 
levamisole and pyrantel pamoate. In contrast, emodep-
side was very active in vitro against the larvae and adult 
worms of all three species. In vivo, albendazole was the 
only drug that performed as well as emodepside on A. 
ceylanicum infected hamsters (Table  4). While none of 
Table 2 In vivo dose response relationships of emodepside on A. ceylanicum, N. americanus and T. muris 
a Kruskal-Wallis test was applied to determine statistical significance on worm burden reduction of all doses versus controls
c Control 1 was used for this dose
d Control 2 was used for this dose
Dose (mg/kg) Mean no. of worms ± SD Worm expulsion 
rate (%)
Worm burden 
reduction (%)
P-value ED50 (mg/kg)
T. muris
 Emodepside 75c 0 100 100 0.007a 1.2
10c 18.8 ± 20.8 62.0 85.9
2.5c 36.5 ± 30.8 60.9 69.6
1.25d 133 ± 27.9 5.3 73.9
 Control  1c 120.8 ± 12.0 0 –
 Control  2d 121.7 ± 4.7 0 –
A. ceylanicum
 Emodepside 2.5 0 100 100 0.014a
 Control 21.3 ± 2.6 0.6 –
N. americanus
 Emodepside 10c 0 100 100 0.060a 0.5
5c 0 100 100
2.5d 0.25 ± 0.5 87.5 93.8
1.25d 2.25 ± 2.3 40.0 43.8
 Control  1c 5.5 ± 6.1 5.6 –
 Control  2d 4.0 ± 1.4 0 –
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the three standard drugs cured mice harboring a T. muris 
infection, emodepside was fully active at a concentration 
of 75 mg/kg.
Although emodepside was also very active in vitro on 
H. polygyrus L3 (with  IC50 values below 1 µM), previous 
studies reported lower in vivo sensitivity of H. polygyrus 
larvae compared to the larval stages of other nematode 
species. This decreased activity against H. polygyrus lar-
vae in vivo was explained by their presence burrowed 
deep into the gastro-intestinal tissues which was likely 
to protect them from the drug [29, 41]. Aiming at a for-
mulation of emodepside active on all parasite stages, in 
vivo studies should preferably be performed at both early 
and late stages of infection. Hence future in vivo studies 
should evaluate the activity against the early develop-
mental stages of the nematodes.
In our study, the in vitro activity of emodepside against 
the nematode species was higher in adult worms than in 
the larvae. Such difference in anthelmintic susceptibil-
ity between the early and the late developmental stages 
of the parasite was reported previously [42–44]. A dif-
ferential expression of emodepside molecular target(s) 
between the parasites life-stages or differences in the 
permeability of the cuticle (or both) may account for it 
[42, 45]. Moreover, a similar trend was observed in vivo 
in other studies on Nippostrongylus brasiliensis, S. ratti 
and H. polygyrus [29]. However, for S. mansoni, we docu-
mented the opposite finding, with revealing lower  IC50 
values than the adults.
We observed in our in vitro studies that whereas the 
morphology of the parasites seemed not affected by the 
drug, often no motility or pharyngeal pumping move-
ment could be detected. This observation corroborates 
the suggested mechanism of action of emodepside [30, 
37, 46–49]. Although its exact mechanism of action is not 
fully understood yet, the drug is known to bind to two 
different targets of the neuromuscular junction, the evo-
lutionary conserved calcium-activated potassium chan-
nel slowpoke 1 (SLO-1) and the latrophilin receptors 
LAT-1/LAT-2 [30, 37, 47, 50, 51]. In nematodes, the over 
activation of the SLO-1 receptors by emodepside is likely 
to induce a potassium efflux triggering a hyperpolariza-
tion of the neurons that results in a decreased synaptic 
Table 3 Mean  IC50 values (µg/ml) after 72 hours drug exposure on L3 and adult stages of A. ceylanicum, N. americanus and T. muris of 
emodepside compared to the ones of albendazole, levamisole and pyrantel pamoate
a All values for this drug are taken from the study of Tritten et al. [36]
Species Mean  IC50 (µg/ml) after 72 hours of drug incubation
Emodepside Albendazolea Levamisole-HCla Pyrantel  pamoatea
T. muris (L1) after 24 h 4.18
T. muris (L3) – ≥ 200 33.1 95.5
T. muris (adults) 0.022 ≥ 200 16.5 34.1
A. ceylanicum (L3) 0.28 32.40 1.60 90.9
A. ceylanicum (adults) 0.0027 ≥ 100 ≥ 100 ≥ 100
N. americanus (L3) 0.090 ≥ 100 0.50 2.0
N. americanus (adults) 0.0024 ≥ 100 13.40 7.6
Table 4 In vivo dose response relationships of emodepside, 
albendazole, levamisole and pyrantel pamoate on A. ceylanicum, 
N. americanus and T. muris 
a All values for this drug are taken from the study of Tritten et al. [36]
Drug Dose (mg/kg) Worm 
expulsion rate 
(%)
Worm burden 
reduction (%)
T. muris
 Emodepside 75 100 100
10 62.0 85.9
2.5 60.9 69.6
1.25 5.3 73.9
 Albendazolea 600 49.4 20.2
 Levamisole-HCla 200 90.5 95.9
 Pyrantel  pamoatea 300 9.4 0
A. ceylanicum
 Emodepside 2.5 100 100
 Albendazolea 1.25 70.5 87.8
2.5 100 100
5 100 100
 Levamisole-HCla 10 44.3 60.2
 Pyrantel  pamoatea 10 63.4 87.2
N. americanus
 Emodepside 10 100 100
5 100 100
2.5 87.5 100
1.25 40.0 62.5
 Albendazolea 10 100 100
5 69.6 70.8
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transmission and muscle contraction, leading notably to 
a paralysis of the worm pharynx [37, 42, 47, 50, 52]. The 
specificity of emodepside towards the nematode channel 
subunits might account for its lack of efficacy against the 
trematodes [49].
The in vitro assay read-out methods varied among the 
different parasites and life-stages. While visual scoring 
of adult worms is generally straightforward for a trained 
operator, evaluating larval assays was more challeng-
ing, especially for T. muris and S. ratti larval assays. This 
led to a high variability between the different assays and 
explained a higher number of replicates reported com-
pared to the other parasites. This finding urges the opti-
mization and development of more accurate assessment 
methods.
Conclusions
Our study confirms that emodepside represents a prom-
ising broad spectrum human anthelmintic drug candidate 
with intriguing activity against a wide range of nema-
todes. Since emodepside is already well characterized 
in veterinary medicine and undergoing clinical develop-
ment for onchocerciasis, and the activity observed in this 
study against different nematodes was similar to previous 
findings on filarial worms [26] this will allow a significant 
shortcut developing this drug for human STH. A drug 
development plan should therefore be established to fill 
the missing gaps required so that emodepside will soon 
be available for the treatment of both filarial and STH 
infections.
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